Inovio Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INO)

$4.22 0.00 (0.00 %)
(As of 02/22/2018 02:00 PM ET)
Previous Close$4.22
Today's Range$4.17 - $4.30
52-Week Range$3.76 - $9.86
Volume680,300 shs
Average Volume1.55 million shs
Market Capitalization$382.85 million
P/E Ratio-3.59
Dividend YieldN/A
Beta2.54

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:INO
CUSIPN/A
Phone+1-858-5976006

Debt

Debt-to-Equity RatioN/A
Current Ratio4.63%
Quick Ratio4.63%

Price-To-Earnings

Trailing P/E Ratio-3.59322033898305
Forward P/E Ratio-3.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.37 million
Price / Sales10.77
Cash FlowN/A
Price / CashN/A
Book Value$1.67 per share
Price / Book2.53

Profitability

Trailing EPS($1.18)
Net Income$-73,740,000.00
Net Margins-221.55%
Return on Equity-72.19%
Return on Assets-53.91%

Miscellaneous

Employees253
Outstanding Shares90,300,000

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?

Inovio Pharmaceuticals declared a monthly dividend on Thursday, September 21st. Stockholders of record on Friday, September 29th will be paid a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 19.62%. The ex-dividend date is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals's stock reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) posted its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.15. The biopharmaceutical company had revenue of $2.60 million for the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm's revenue for the quarter was down 79.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.28) EPS. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2018?

10 brokerages have issued 1-year target prices for Inovio Pharmaceuticals' stock. Their predictions range from $8.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $19.80 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year." (1/9/2018)
  • 2. Maxim Group analysts commented, "Inovio announced an amended agreement with ApolloBio (NEEQ: 430187) to develop and commercialize VGX-3100 for precancerous HPV (human papillomavirus) infections and dysplasias (cervical, vulvar, anal) in Greater China (China, Hong Kong, Macao, Taiwan, potentially Korea too). Inovio will receive an upfront payment of $23M plus milestones and royalties. The deal is expected to close in 1Q18." (1/2/2018)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Peter D. Kies, Chief Financial Officer (Age 53)
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
  • Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
  • George W. Bickerstaff III, Director (Age 62)
  • David B. Weiner, Director (Age 61)
  • Wendy L. Yarno, Director (Age 63)
  • Simon X. Benito, Independent Director (Age 72)

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.34%), Wasatch Advisors Inc. (2.95%), Geode Capital Management LLC (0.92%), Deutsche Bank AG (0.50%), Renaissance Technologies LLC (0.40%) and Bank of New York Mellon Corp (0.40%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, TIAA CREF Investment Management LLC, BlackRock Inc., Wasatch Advisors Inc., Bank of New York Mellon Corp, Goldman Sachs Group Inc. and Virtu Financial LLC. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG, ARK Investment Management LLC, Vident Investment Advisory LLC, Stansberry Asset Management LLC, Virtus Fund Advisers LLC, Geode Capital Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $4.22.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $382.85 million and generates $35.37 million in revenue each year. The biopharmaceutical company earns $-73,740,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Inovio Pharmaceuticals employs 253 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 10480 Wateridge Cir, SAN DIEGO, CA 92121-5773, United States. The biopharmaceutical company can be reached via phone at +1-858-5976006 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (INO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  360 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  556
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Inovio Pharmaceuticals (NASDAQ:INO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.802.78
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.80$20.20$20.20$22.11
Price Target Upside: 373.68% upside335.34% upside336.29% upside307.20% upside

Inovio Pharmaceuticals (NASDAQ:INO) Consensus Price Target History

Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018Maxim GroupLower Price TargetBuy -> Buy$12.00 -> $8.00LowView Rating Details
2/13/2018HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
10/18/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$11.00N/AView Rating Details
10/6/2017CitigroupInitiated CoverageBuy$10.00N/AView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies GroupReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
5/25/2016National Bank FinancialDowngradeOutperform Market Weight -> Sector Perform Market WeightN/AView Rating Details
3/28/2016DesjardinsDowngradeBuy -> HoldN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Inovio Pharmaceuticals (NASDAQ:INO) Earnings History and Estimates Chart

Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 17($0.25)($0.40)$10.27 million$2.60 millionViewN/AView Earnings Details
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/15/2014$0.22$0.22$4.63 million$4.66 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
5/7/2014$0.20$0.23$4.63 million$4.89 millionViewN/AView Earnings Details
3/22/2014$0.20$0.24ViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.08)($0.20)$1.60 million$0.79 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.16)$1.45 million$1.46 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.16)($0.08)ViewN/AView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.16)($0.17)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.16)($0.19)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.20)($0.16)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.12)($0.15)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.20)($0.09)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.16)($0.09)ViewN/AView Earnings Details
3/17/2011Q4 2010($0.16)($0.24)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.12)($0.06)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.08)($0.30)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.16)($0.13)ViewN/AView Earnings Details
3/29/2010Q4 2009($0.20)($0.28)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.20)($0.12)ViewN/AView Earnings Details
8/19/2009Q2 2009($0.24)($0.24)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.32)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.32)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.21)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.37)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.28)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.44)($0.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Inovio Pharmaceuticals (NASDAQ:INO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-1.26 EPS

Dividends

Inovio Pharmaceuticals (NASDAQ:INO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/21/2017Monthly$0.079/28/20179/29/201710/16/2017
8/22/2017Monthly$0.078/29/20178/31/20179/15/2017
7/25/2017Monthly$0.077/27/20177/31/20178/15/2017
6/23/2017Monthly$0.076/28/20176/30/20177/17/2017
(Data available from 1/1/2013 forward)

Insider Trades

Inovio Pharmaceuticals (NASDAQ INO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 33.42%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00740,956View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.202,164,887View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00142,291View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.0070,234View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00142,291View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.5024,048View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00127,291View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.0032,000View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.005,965,809View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00655,864View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Inovio Pharmaceuticals (NASDAQ INO) News Headlines

Source:
DateHeadline
Inovio Pharmaceuticals Inc (INO) Receives Consensus Rating of "Hold" from BrokeragesInovio Pharmaceuticals Inc (INO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 20 at 1:36 AM
HC Wainwright Reiterates "$13.00" Price Target for Inovio Pharmaceuticals (INO)HC Wainwright Reiterates "$13.00" Price Target for Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - February 18 at 7:00 PM
BioXcel Therapeutics Seeks $69 Million U.S. IPOBioXcel Therapeutics Seeks $69 Million U.S. IPO
seekingalpha.com - February 16 at 3:10 PM
Inovio Pharmaceuticals (INO) PT Lowered to $8.00 at Maxim GroupInovio Pharmaceuticals (INO) PT Lowered to $8.00 at Maxim Group
www.americanbankingnews.com - February 15 at 1:26 PM
 Brokerages Anticipate Inovio Pharmaceuticals Inc (INO) to Announce -$0.29 EPS Brokerages Anticipate Inovio Pharmaceuticals Inc (INO) to Announce -$0.29 EPS
www.americanbankingnews.com - February 14 at 5:18 PM
Inovio and The Wistar Institute Receive More Than $4.6 Million in ... - GlobeNewswire (press release)Inovio and The Wistar Institute Receive More Than $4.6 Million in ... - GlobeNewswire (press release)
globenewswire.com - February 12 at 3:07 PM
Inovio lands $4.6M in funding for malaria, tuberculosis vaccinesInovio lands $4.6M in funding for malaria, tuberculosis vaccines
finance.yahoo.com - February 12 at 3:07 PM
Inovio Pharmaceuticals to Participate in Upcoming Investment ... - GlobeNewswire (press release)Inovio Pharmaceuticals to Participate in Upcoming Investment ... - GlobeNewswire (press release)
www.globenewswire.com - February 6 at 5:03 AM
Inovio Pharmaceuticals (INO) Downgraded by BidaskClub to "Strong Sell"Inovio Pharmaceuticals (INO) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - February 3 at 2:44 PM
Inovio Pharmaceuticals Inc (INO) Expected to Post Quarterly Sales of $7.75 MillionInovio Pharmaceuticals Inc (INO) Expected to Post Quarterly Sales of $7.75 Million
www.americanbankingnews.com - January 30 at 2:32 AM
Inovio Pharmaceuticals (INO) Upgraded at BidaskClubInovio Pharmaceuticals (INO) Upgraded at BidaskClub
www.americanbankingnews.com - January 29 at 12:28 AM
Inovio Pharmaceuticals Inc (INO) Expected to Announce Earnings of -$0.29 Per ShareInovio Pharmaceuticals Inc (INO) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - January 28 at 5:12 PM
Inovio Pharmaceuticals Sees Unusually High Options Volume (INO)Inovio Pharmaceuticals Sees Unusually High Options Volume (INO)
www.americanbankingnews.com - January 27 at 2:32 AM
Inovio Pharmaceuticals Inc (INO) Receives Average Recommendation of "Hold" from AnalystsInovio Pharmaceuticals Inc (INO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 26 at 1:24 AM
Here's Why Inovio Pharmaceuticals Rose as Much as 26.7% TodayHere's Why Inovio Pharmaceuticals Rose as Much as 26.7% Today
finance.yahoo.com - January 25 at 5:10 AM
Inovio Drops 11% One Day After Soaring on Flu Vaccine HopesInovio Drops 11% One Day After Soaring on Flu Vaccine Hopes
finance.yahoo.com - January 25 at 5:10 AM
Inovios Influenza Vaccine Shows Potential, Shares Rally - NasdaqInovio's Influenza Vaccine Shows Potential, Shares Rally - Nasdaq
www.nasdaq.com - January 24 at 3:13 PM
HC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price TargetHC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price Target
www.americanbankingnews.com - January 23 at 8:08 AM
Inovio Pharmaceuticals Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major ... - GlobeNewswire (press release)Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major ... - GlobeNewswire (press release)
globenewswire.com - January 22 at 3:17 PM
Inovios investigational flu vaccine shows broad protection in preclinical studies; shares up 4% - Seeking AlphaInovio's investigational flu vaccine shows broad protection in preclinical studies; shares up 4% - Seeking Alpha
seekingalpha.com - January 22 at 3:17 PM
Inovio Pharmaceuticals Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal ModelsInovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models
finance.yahoo.com - January 22 at 3:17 PM
Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016
finance.yahoo.com - January 17 at 8:46 AM
Pediatric Vaccines Market Worth $60.4 Billion by 2025 | CAGR: 11.7%: Grand View Research, Inc.Pediatric Vaccines Market Worth $60.4 Billion by 2025 | CAGR: 11.7%: Grand View Research, Inc.
www.bizjournals.com - January 15 at 5:45 PM
Reviewing Inovio Pharmaceuticals (INO) and Aptose Biosciences (APTO)Reviewing Inovio Pharmaceuticals (INO) and Aptose Biosciences (APTO)
www.americanbankingnews.com - January 15 at 5:38 AM
$7.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter$7.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter
www.americanbankingnews.com - January 13 at 8:30 AM
-$0.29 Earnings Per Share Expected for Inovio Pharmaceuticals Inc (INO) This Quarter-$0.29 Earnings Per Share Expected for Inovio Pharmaceuticals Inc (INO) This Quarter
www.americanbankingnews.com - January 11 at 7:32 PM
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development ... - GlobeNewswire (press release)Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development ... - GlobeNewswire (press release)
globenewswire.com - January 10 at 8:19 AM
Montco biopharm to collaborate with the Parker Institute for Cancer Immunotherapy - Philadelphia Business JournalMontco biopharm to collaborate with the Parker Institute for Cancer Immunotherapy - Philadelphia Business Journal
www.bizjournals.com - January 10 at 8:19 AM
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy CombinationsInovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
finance.yahoo.com - January 9 at 8:44 AM
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in ... - GlobeNewswire (press release)Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in ... - GlobeNewswire (press release)
globenewswire.com - January 8 at 10:49 AM
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
finance.yahoo.com - January 8 at 10:49 AM
1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December - Motley Fool1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December - Motley Fool
www.fool.com - January 6 at 8:12 AM
1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December
finance.yahoo.com - January 5 at 5:30 PM
Inovio Pharmaceuticals (INO) Stock Rating Reaffirmed by HC WainwrightInovio Pharmaceuticals (INO) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - January 3 at 8:22 AM
Why Inovio Pharmaceuticals Inc. Is Soaring Today - Motley FoolWhy Inovio Pharmaceuticals Inc. Is Soaring Today - Motley Fool
www.fool.com - January 3 at 8:13 AM
Why Inovio Pharmaceuticals Inc. Is Soaring TodayWhy Inovio Pharmaceuticals Inc. Is Soaring Today
finance.yahoo.com - January 2 at 7:23 PM
Inovio Pharma (INO) Enters Pact with ApolloBio to Develop and ... - StreetInsider.comInovio Pharma (INO) Enters Pact with ApolloBio to Develop and ... - StreetInsider.com
www.streetinsider.com - January 2 at 3:30 PM
Inovio Poised For Breakthroughs In 2018 And Beyond - Seeking AlphaInovio Poised For Breakthroughs In 2018 And Beyond - Seeking Alpha
seekingalpha.com - January 2 at 3:30 PM
Inovio revamps China deal; nets $23M upfront paymentInovio revamps China deal; nets $23M upfront payment
finance.yahoo.com - January 2 at 3:30 PM
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater ChinaInovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
finance.yahoo.com - January 2 at 8:16 AM
Inovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Hold" by BrokeragesInovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 1 at 2:30 AM
ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 28, 2017ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:29 PM
Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 9:55 AM
Innoviva and Sarissa Implement Court OrderInnoviva and Sarissa Implement Court Order
www.businesswire.com - December 19 at 5:45 PM
Heres Why Inovio Pharmaceuticals Inc. Fell 21.3% in November - Motley FoolHere's Why Inovio Pharmaceuticals Inc. Fell 21.3% in November - Motley Fool
www.fool.com - December 12 at 3:24 PM
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development - GlobeNewswire (press release)Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development - GlobeNewswire (press release)
globenewswire.com - December 11 at 9:42 AM
Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound? - NasdaqInovio (INO) Down 15.5% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - December 11 at 9:42 AM
Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?
finance.yahoo.com - December 11 at 9:42 AM
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & DevelopmentInovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
finance.yahoo.com - December 11 at 9:42 AM
Zacks: Brokerages Expect Inovio Pharmaceuticals, Inc. (INO) Will Announce Quarterly Sales of $7.75 MillionZacks: Brokerages Expect Inovio Pharmaceuticals, Inc. (INO) Will Announce Quarterly Sales of $7.75 Million
www.americanbankingnews.com - December 10 at 7:54 AM

SEC Filings

Inovio Pharmaceuticals (NASDAQ:INO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Inovio Pharmaceuticals (NASDAQ:INO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Inovio Pharmaceuticals (NASDAQ INO) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.